GlassScriptPhysician profile
Jeremy Clark
NPI 1073838850
$130,862.87
in general payments reported to CMS, 2019-2025
18 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $1,785 · 2021: $26K · 2022: $28K · 2023: $24K · 2024: $28K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Honoraria: $20K · Consulting Fee: $6,300 · Travel and Lodging: $5,884 · Food and Beverage: $4,761 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,800.00 |
| Honoraria | $20,087.50 |
| Consulting Fee | $6,300.00 |
| Travel and Lodging | $5,884.02 |
| Food and Beverage | $4,760.74 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $76,162.55 | 2020-2023 | Tepezza |
| Amgen INC. | $50,082.98 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $3,259.46 | 2019-2021 | |
| Alcon Vision LLC | $266.38 | 2019-2023 | Simbrinza, Rhopressa, Rocklatan |
| Axogen | $184.76 | 2020-2021 | |
| Glaukos Corporation | $141.68 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $131.26 | 2023 | |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Allergan, INC. | $107.60 | 2019 | |
| Mallinckrodt Enterprises LLC | $105.11 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $85.42 | 2024 | Tecnis Simplicity |
| Ani Pharmaceuticals, INC. | $75.47 | 2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $40.97 | 2020-2021 | |
| Stryker Corporation | $35.96 | 2024 | Medpor Titan |
| Merz Pharmaceuticals, LLC | $21.40 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $15.95 | 2020 | |
| Ocular Therapeutix, INC. | $13.99 | 2023 | Dextenza |
| Pacira Pharmaceuticals Incorporated | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.